AI and rising trial success rates are changing the investor outlook
AI is changing the economics of the outsourced pharma-services market. But will it hurt CROs by making drug development more successful, or create a much larger market by getting more drugs through to expensive later-stage trials? In a detailed new analysis for Healthcare Today, Candesic managing partner Dr Leonid Shapiro examines what the rise of AI-discovered drugs could mean for…
Candesic is CDD Provider of the Year at European Private Equity Awards 2026
Candesic has been named Commercial Due Diligence Provider of the Year at the European Private Equity Awards 2026. We are particularly pleased to have received the award this year, as for the first time Mergermarket expanded the remit to include submissions from across Europe. The standard of competition was high, and entries were assessed by an independent panel of judges…
Marc Kitten joins HPE Europe 2026 panel on Exits and Strategic Buyers
It was great to see so many familiar faces and to make new connections at HPE Europe 2026.Candesic Senior Partner Marc Kitten joined a phenomenal panel on “Exits unlocked: The increasing role of the strategic buyer” stage alongside Adam Feinstein, Michael Ruoff, Cleaver Sower, Ellie West and Jason Zemmel.Congratulations to McDermott Will & Schulte on hosting such a successful event.…
Candesic hosts Oxford Lifesciences Dinner at Magdalen College
Huge thanks to all who attended the Oxford Lifesciences Dinner at the historic New Room at Magdalen College, Oxford last night.The event brought together senior industry figures from life sciences companies and investors at the forefront of driving positive change in the sector for an entertaining evening filled with free flowing conversation co-hosted by Candesic, Winston Taylor and Stifel Financial…
Candesic has been shortlisted as a finalist for Consultancy of the Year at the LaingBuisson Awards 2026
We are delighted to share that Candesic has been shortlisted again as a finalist for Consultancy of the Year at the LaingBuisson Awards 2026.Having won this award in 2025, we are incredibly proud to have made the finalist list this year. This recognition reflects the continuing dedication, expertise and impact of our team, and the trust our clients place in…
Candesic advises investor consortium on £1bn Spire acquisition
Leading UK-based independent hospital and healthcare group Spire Healthcare has recommended a £1bn takeover by an investor consortium indirectly owned by investment firm Toscafund Asset Management, private equity firm Three Hills (THCP Advisory), and US investment manager Ares Management. Candesic is delighted to have provided commercial due diligence to this consortium through Tulip UK Bidco, their newly formed acquisition vehicle.…
Candesic shortlisted for CDD Provider of the Year by Mergermarket
Candesic has today (Monday, September 7) been shortlisted for Commercial Due Diligence Provider of the Year at the Mergermarket European Private Equity Awards 2026!We are proud to see the team’s hard work recognised, and grateful to our clients for the trust they continue to place in us.As of today, voting is now open – but not for long! The final…
Introducing Candesic’s 2026 Analyst Cohort!
We are kicking off training for an outstanding group of ambitious and talented individuals joining Candesic.We are delighted to welcome our new full-time Analysts:Amanda Liu, Andre Johannesen, Deeplata Jha, Hersh Punjani, Joe Turner and Thomas Künow.We are also very pleased to welcome Maria Vara as Senior Analyst and our new Interns: Hugo Baumgartner, Max Carnegie Brown and Dr. Toby Speirs.Each…
Candesic advises Everlight Radiology on AUD1bn acquisition by Radiology Partners
Candesic has provided AI vendor commercial due diligence to Everlight Radiology in support of its AUD1bn acquisition by Radiology Partners, the leading provider of technology and AI-enabled radiology services in the US. The transaction will bring together Everlight’s international teleradiology network with Radiology Partners’ vRad platform, creating a leading global teleradiology business. The combination will connect the organisations’ technology, clinical…
Candesic advises ARCHIMED on investment in Renata Medical
Paediatric medical device company Renata Medical has just closed a $25m Series D financing round. The round was led by global private equity investment firm ARCHIMED Candesic is delighted to have supported ARCHIMED with commercial due diligence on the investment in Renata, a US-based technology company focused on developing cardiovascular devices specifically for children with congenital heart disease. The Candesic…
Candesic provides VCDD as Columna Capital sells Ardentis Cliniques Dentaires
Candesic is delighted to have provided vendor commercial due diligence to Ardentis Cliniques Dentaires on its sale to Medbase Group, which is acquiring a majority stake in the Swiss dental and orthodontic clinic network from British private equity firm Columna Capital. The Candesic team was led by Senior Partner Marc Kitten, assisted by Senior Advisor in Dental Dr Marco Mazevet.…
UK fertility: How social media is reshaping the market
The UK fertility market is being reshaped by a shift towards private funding, changing patient demographics and rapid technological change. But is that the full story? In the latest edition of LaingBuisson’s HealthcareMarkets, Candesic Senior Partner Michelle Tempest, Senior Engagement Manager Chris Cassar and Director of Content David Farbrother examine the forces transforming the UK fertility market. The article explores:…